Equities research analysts predict that Sutro Biopharma Inc (NASDAQ:STRO) will report ($0.59) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Sutro Biopharma’s earnings. The lowest EPS estimate is ($0.75) and the highest is ($0.47). Sutro Biopharma reported earnings of ($0.60) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 1.7%. The firm is scheduled to announce its next earnings results on Wednesday, August 12th.

According to Zacks, analysts expect that Sutro Biopharma will report full-year earnings of ($2.70) per share for the current fiscal year, with EPS estimates ranging from ($3.20) to ($2.24). For the next financial year, analysts expect that the firm will report earnings of ($2.55) per share, with EPS estimates ranging from ($3.45) to ($1.67). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Sutro Biopharma.

Sutro Biopharma (NASDAQ:STRO) last issued its earnings results on Monday, May 11th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.15). Sutro Biopharma had a negative return on equity of 59.70% and a negative net margin of 148.06%. The firm had revenue of $7.15 million for the quarter, compared to analysts’ expectations of $11.16 million.

A number of brokerages have commented on STRO. Zacks Investment Research raised shares of Sutro Biopharma from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research note on Tuesday, July 14th. B. Riley cut shares of Sutro Biopharma to a “hold” rating in a research report on Tuesday, May 12th. Wells Fargo & Co initiated coverage on shares of Sutro Biopharma in a research report on Thursday, July 16th. They set an “overweight” rating and a $18.00 price target for the company. Piper Sandler dropped their price target on shares of Sutro Biopharma from $23.00 to $20.00 in a research report on Monday, May 18th. Finally, HC Wainwright dropped their price target on shares of Sutro Biopharma from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. Sutro Biopharma currently has a consensus rating of “Buy” and a consensus price target of $16.86.

STRO stock traded down $0.20 during trading on Friday, reaching $7.77. 158,479 shares of the stock were exchanged, compared to its average volume of 108,503. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.98 and a quick ratio of 3.98. The business has a 50 day moving average price of $8.50 and a 200-day moving average price of $9.74. Sutro Biopharma has a 1 year low of $6.00 and a 1 year high of $12.75.

In other news, CEO William J. Newell purchased 64,516 shares of the stock in a transaction on Thursday, May 14th. The stock was bought at an average price of $7.75 per share, for a total transaction of $499,999.00. Following the acquisition, the chief executive officer now directly owns 166,627 shares of the company’s stock, valued at approximately $1,291,359.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Arturo Md Molina purchased 6,451 shares of the stock in a transaction on Thursday, May 14th. The shares were purchased at an average price of $7.75 per share, with a total value of $49,995.25. Following the acquisition, the insider now directly owns 12,083 shares in the company, valued at $93,643.25. The disclosure for this purchase can be found here. Insiders own 28.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Eventide Asset Management LLC grew its holdings in Sutro Biopharma by 3.3% during the 1st quarter. Eventide Asset Management LLC now owns 1,285,975 shares of the company’s stock worth $13,117,000 after acquiring an additional 41,080 shares in the last quarter. BlackRock Inc. lifted its position in shares of Sutro Biopharma by 2.1% during the 1st quarter. BlackRock Inc. now owns 660,751 shares of the company’s stock worth $6,738,000 after buying an additional 13,644 shares during the last quarter. Driehaus Capital Management LLC lifted its position in shares of Sutro Biopharma by 3.0% during the 1st quarter. Driehaus Capital Management LLC now owns 289,306 shares of the company’s stock worth $2,951,000 after buying an additional 8,372 shares during the last quarter. State Street Corp lifted its position in shares of Sutro Biopharma by 5.4% during the 1st quarter. State Street Corp now owns 178,605 shares of the company’s stock worth $1,822,000 after buying an additional 9,139 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its position in shares of Sutro Biopharma by 524.8% during the 1st quarter. Janus Henderson Group PLC now owns 168,246 shares of the company’s stock worth $1,714,000 after buying an additional 141,318 shares during the last quarter. Institutional investors own 51.10% of the company’s stock.

About Sutro Biopharma

Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.

Featured Story: Basic Economics

Get a free copy of the Zacks research report on Sutro Biopharma (STRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sutro Biopharma (NASDAQ:STRO)

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.